DSM-Firmenich AG (DSFIR) - Net Assets
Based on the latest financial reports, DSM-Firmenich AG (DSFIR) has net assets worth €18.42 Billion EUR (≈ $21.54 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€29.34 Billion ≈ $34.31 Billion USD) and total liabilities (€10.92 Billion ≈ $12.77 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is DSM-Firmenich AG's balance sheet for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €18.42 Billion |
| % of Total Assets | 62.78% |
| Annual Growth Rate | 9.65% |
| 5-Year Change | 96.05% |
| 10-Year Change | 198.11% |
| Growth Volatility | 32.14 |
DSM-Firmenich AG - Net Assets Trend (2013–2025)
This chart illustrates how DSM-Firmenich AG's net assets have evolved over time, based on quarterly financial data. For live valuation and market cap data, see DSFIR market cap.
Annual Net Assets for DSM-Firmenich AG (2013–2025)
The table below shows the annual net assets of DSM-Firmenich AG from 2013 to 2025. Explore DSM-Firmenich AG cash conversion from operations to assess how effectively this company generates cash.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €18.42 Billion ≈ $21.54 Billion |
-18.83% |
| 2024-12-31 | €22.70 Billion ≈ $26.54 Billion |
-1.62% |
| 2023-12-31 | €23.07 Billion ≈ $26.97 Billion |
+112.72% |
| 2022-12-31 | €10.85 Billion ≈ $12.68 Billion |
+15.41% |
| 2021-12-31 | €9.40 Billion ≈ $10.99 Billion |
+25.51% |
| 2020-12-31 | €7.49 Billion ≈ $8.75 Billion |
-4.44% |
| 2019-12-31 | €7.83 Billion ≈ $9.16 Billion |
+0.26% |
| 2018-12-31 | €7.82 Billion ≈ $9.14 Billion |
+10.62% |
| 2017-12-31 | €7.07 Billion ≈ $8.26 Billion |
+14.32% |
| 2016-12-31 | €6.18 Billion ≈ $7.23 Billion |
+9.75% |
| 2015-12-31 | €5.63 Billion ≈ $6.58 Billion |
-5.14% |
| 2014-12-31 | €5.94 Billion ≈ $6.94 Billion |
-2.62% |
| 2013-12-31 | €6.10 Billion ≈ $7.13 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to DSM-Firmenich AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €18.24 Billion | 100.00% |
| Total Equity | €18.24 Billion | 100.00% |
DSM-Firmenich AG Competitors by Market Cap
The table below lists competitors of DSM-Firmenich AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AIB Group PLC
IR:A5G
|
$18.42 Billion |
|
Tourmaline Oil Corp.
TO:TOU
|
$18.42 Billion |
|
COCA COLA HBC AG ADRS
F:CCKC
|
$18.44 Billion |
|
Heineken Holding NV
AS:HEIO
|
$18.45 Billion |
|
Zhongjin Gold Corp Ltd
SHG:600489
|
$18.41 Billion |
|
Ke Holdings Inc
NYSE:BEKE
|
$18.41 Billion |
|
Knorr-Bremse AG
F:KBX
|
$18.41 Billion |
|
ideaForge Technology Limited
NSE:IDEAFORGE
|
$18.41 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DSM-Firmenich AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 22,511,000,000 to 18,244,000,000, a change of -4,267,000,000 (-19.0%).
- Net loss of 1,081,000,000 reduced equity.
- Dividend payments of 718,000,000 reduced retained earnings.
- Share repurchases of 1,181,000,000 reduced equity.
- Other comprehensive income decreased equity by 710,000,000.
- Other factors decreased equity by 577,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-1.08 Billion | -5.93% |
| Dividends Paid | €718.00 Million | -3.94% |
| Share Repurchases | €1.18 Billion | -6.47% |
| Other Comprehensive Income | €-710.00 Million | -3.89% |
| Other Changes | €-577.00 Million | -3.16% |
| Total Change | €- | -18.96% |
Book Value vs Market Value Analysis
This analysis compares DSM-Firmenich AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.90x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.87x to 0.90x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | €34.07 | €63.56 | x |
| 2014-12-31 | €33.01 | €63.56 | x |
| 2015-12-31 | €31.67 | €63.56 | x |
| 2016-12-31 | €34.56 | €63.56 | x |
| 2017-12-31 | €39.67 | €63.56 | x |
| 2018-12-31 | €44.13 | €63.56 | x |
| 2019-12-31 | €43.72 | €63.56 | x |
| 2020-12-31 | €42.91 | €63.56 | x |
| 2021-12-31 | €53.84 | €63.56 | x |
| 2022-12-31 | €61.99 | €63.56 | x |
| 2023-12-31 | €98.23 | €63.56 | x |
| 2024-12-31 | €85.08 | €63.56 | x |
| 2025-12-31 | €70.36 | €63.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DSM-Firmenich AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -11.97%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.61x
- Recent ROE (-5.93%) is below the historical average (7.09%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 4.27% | 2.84% | 0.74x | 2.01x | €-338.80 Million |
| 2014 | 2.15% | 1.74% | 0.58x | 2.12x | €-449.30 Million |
| 2015 | 3.14% | 2.25% | 0.66x | 2.12x | €-380.10 Million |
| 2016 | 10.62% | 8.14% | 0.61x | 2.13x | €37.80 Million |
| 2017 | 25.29% | 20.40% | 0.67x | 1.84x | €1.06 Billion |
| 2018 | 13.74% | 11.54% | 0.68x | 1.75x | €290.80 Million |
| 2019 | 8.73% | 8.44% | 0.59x | 1.74x | €-98.10 Million |
| 2020 | 6.05% | 5.53% | 0.57x | 1.94x | €-291.90 Million |
| 2021 | 9.36% | 7.62% | 0.71x | 1.72x | €-59.80 Million |
| 2022 | 4.28% | 5.48% | 0.48x | 1.62x | €-614.30 Million |
| 2023 | 9.33% | 20.11% | 0.31x | 1.50x | €-153.80 Million |
| 2024 | 1.11% | 1.95% | 0.38x | 1.50x | €-2.00 Billion |
| 2025 | -5.93% | -11.97% | 0.31x | 1.61x | €-2.91 Billion |
Industry Comparison
This section compares DSM-Firmenich AG's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $1,934,295,000
- Average return on equity (ROE) among peers: -10.71%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DSM-Firmenich AG (DSFIR) | €18.42 Billion | 4.27% | 0.59x | $18.41 Billion |
| Akzo Nobel NV (AKZA) | $7.36 Billion | -29.48% | 1.44x | $9.97 Billion |
| Avantium Holding BV (AVTX) | $50.03 Million | -48.81% | 0.55x | $157.81 Million |
| Corbion NV (CRBN) | $948.30 Million | -18.38% | 1.55x | $1.24 Billion |
| Holland Colours NV (HOLCO) | $58.81 Million | 9.98% | 0.25x | $81.30 Million |
| IMCD NV (IMCD) | $653.83 Million | 9.46% | 1.19x | $5.44 Billion |
| OCI NV (OCI) | $2.54 Billion | 12.95% | 3.17x | $761.80 Million |
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through four segments: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health. The Perfumery & Beauty creates scents using natural, sy… Read more